Benzinga | Aug 2, 2021 08:06AM EDT

Avidity Biosciences Receives IND Clearance From FDA To Proceed With Phase 1/2 MARINA Trial Of AOC 1001 In Adults With Myotonic Dystrophy

Avidity Biosciences, Inc. (NASDAQ:RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs(tm)), today announced that the U.S. Food and Drug Administration (FDA) cleared the company to proceed with the Phase 1/2 MARINA(tm) clinical trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1).